JBIO
The table below shows Jade Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q3 2024 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$24.08M | -$18.76M | -$6.80M | -$23.67M | -$11.42M | -$5.66M |
| Capital expenditure | - | - | - | - | $16.00K | $28.00K |
| Investing cash flow | -$8.47M | $12.85M | $0.00 | $8.83M | $15.38M | -$20.40M |
| Dividends paid | - | - | - | - | - |
Jade Biosciences, Inc. reported operating cash flow of -$94.69M for fiscal year 2025. That is down 33.0% from -$71.20M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$7.86M (FY 2020) to -$94.69M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$795.00K | -$700.00K | $94.77M | $471.00K | $223.00K | - |